Glioblastoma is the most common and most aggressive primary malignant brain tumor in adults, with rapid progression and poor overall prognosis. Clinical manifestations vary by tumor location and include headache, seizures, neurologic deficits, and cognitive changes. Standard treatment generally combines surgery, radiotherapy, and temozolomide-based chemotherapy.
A phase I trial and a preclinical study found viral immunotherapy triggered T cell responses in glioblastoma. The clinical study enrolled 41 patients; the mouse study showed prolonged survival and immunologic memory.
Nature Communications findings showed NR2F6 deletion revived exhausted CAR-T cells and boosted activity against solid tumors. In murine models, modified cells drove tumor regression, prolonged survival and resistance to rechallenge.
Wafik S. El-Deiry highlighted p53 research and the August 2025 approval of dordaviprone/modeyso, the first treatment for diffuse gliomas with H3K27M mutations. Separate posts also described glioblastoma precision oncology discussions and a lifetime achievement award in Mumbai.
Tango Therapeutics said it plans to start a pivotal 300-patient randomized vopimetostat trial in second-line pancreatic cancer this year after FDA interactions. The company also reported early combination enrollment with daraxonrasib and zoldonrasib and said more monotherapy and combination data are expected later this year.
Champions Oncology said it will present eight poster presentations at AACR 2026 in San Diego on April 17-22. The studies cover KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, ADCs and CAR-T therapies.
A clinical trial combining laser interstitial thermal therapy with pembrolizumab immunotherapy showed nearly half of recurrent high-grade astrocytoma patients alive at 18 months, far exceeding typical survival. Separate research reveals steroids make glioblastoma cells vulnerable to dietary interventions targeting their altered metabolism.
Researchers have developed new immunotherapy approaches including internal immune cell reprogramming and CD40-based therapies showing promising results in early trials. Meanwhile, glioblastoma remains resistant to current immunotherapies due to blood-brain barrier constraints, though advances in antibody engineering offer new potential strategies.
DelveInsight pipeline reports reveal robust clinical development across three cancer indications, with 45+ companies advancing cutaneous squamous cell carcinoma therapies, 70+ companies developing liver cancer treatments, and multiple hepatocellular carcinoma candidates receiving FDA designations in 2025-2026.
The U.S. FDA has granted Fast Track designation to FluoGuide's FG001 as an intraoperative imaging agent for high-grade glioma surgical resection. The designation follows IND clearance in January and enables accelerated development and regulatory review.
Diakonos Oncology's Phase 2 glioblastoma trial of DOC1021 continues after independent safety review found no concerns. The company will present clinical data on the dendritic cell therapy at AACR and AAN conferences in April 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07604285 |
A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07568782 |
Impact of Fluorescence-Guided Resection and Chemoradiotherapy on the Systemic Immune Response in Glioblastoma: A Kinetic Analysis of Immune Biomarkers. |
NOT_YET_RECRUITING | |
| NCT07560865 |
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma |
RECRUITING | PHASE1 |
| NCT07552467 |
Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors |
RECRUITING | |
| NCT07551336 |
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma |
RECRUITING | PHASE1 |
| NCT07541781 |
Sitagliptin in Recurrent/Progressive Grade 4 Glioma |
NOT_YET_RECRUITING | PHASE1 |
| NCT07532031 |
APT-weighted and Diffusion MRI for Characterizing Tumor Infiltration in High-Grade Gliomas |
NOT_YET_RECRUITING | |
| NCT07515924 |
Oral Gallium Maltolate for Recurrent Glioblastoma |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07499141 |
Use of Fluorescence in Gliomas |
COMPLETED | |
| NCT07493447 |
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures |
NOT_YET_RECRUITING | EARLY_PHASE1 |
